Multi-omic approach classifies biomarkers for paediatric sepsis
Researchers have discovered potential biomarkers to identify paediatric sepsis progression stage, enabling more targeted treatment.
List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
Researchers have discovered potential biomarkers to identify paediatric sepsis progression stage, enabling more targeted treatment.
This eBook explores a new means to perform single-cell functional analysis. Uncover the Xdrop®single-cell format workflow with its ability to help identify, quantify, and comprehend immune cell functions at the individual cellular level.
This guide provides technical background on concepts and techniques for use of Transcreener biochemical assays to measure drug-target residence times.
Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio
A deep learning model developed using circulating cell-free DNA outperformed traditional screening methods for gestational diabetes mellitus.
The Ku70 protein prevents cancer cells from becoming more aggressive and metastasising. It could also be used as an immune biomarker.
How pure consistent and functional lower motor neurons can be precision reprogrammed from iPSCs for motor neuron disease research and drug discovery.
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
Researchers explored the effects of loops and 3D genome organisation on gene silencing, and found that ‘cohesinopathies’ may be linked it.
Learn more about Euretos computational disease model and how it predicts many of the known drug targets for RA.
In this guide, we provide an overview of the DDR and innate immune pathway and describe Transcreener Assays and Assay Systems for key targets.
Tips and tricks for fully leveraging Advanced Flow Cytometry.
3 January 2024 | By Eurofins DiscoverX
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.